Comparative study on the clinical effectiveness of low-concentration cyclosporine eye drops in patients with dry eye disease
PLOS One · 2026
DOI: 10.1371/journal.pone.0358007 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2026. Verfasst von Jae Hyun Kim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Pusan National University School of Medicine, Busan, South Korea. Hauptthemen laut MEDLINE: Cyclosporine, Dry Eye Syndromes, Ophthalmic Solutions. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SCAI Therapeutics.
Abstract (Originalsprache)
Purpose
This study aimed to evaluate the efficacy and safety of low-concentration, nanoparticle-based cyclosporine eye drops (SCAI-001 0.01% and SCAI-001 0.02%) compared to those of the conventional Restasis ® (cyclosporine 0.05%) emulsion for dry eye disease (DED).
Methods
In this multicenter, randomized, double-blind, Phase 2 trial, patients with DED were assigned to three groups: SCAI-001 0.01%, SCAI-001 0.02%, and Restasis. The primary efficacy endpoint was the change in tear volume after 12 weeks. Secondary efficacy endpoints included changes in tear volume at 4 and 8 weeks, corneal and conjunctival surface staining scores, tear film breakup time (TBUT), standard patient evaluation of eye dryness questionnaire score (SPEED), and ocular surface disease index (OSDI) at 4, 8, and 12 weeks.
Results
Tear volume increased in all groups at 12 weeks without intergroup differences. SCAI-001 0.01% and SCAI-001 0.02% achieved earlier improvements in tear volume at 4 weeks than that of Restasis, although no significant between-group difference was observed at any time point. Conjunctival surface scores improved in all groups at 4, 8, and 12 weeks, excluding 4 weeks of Restasis. Conjunctival staining improved to a greater extent with SCAI-001 0.01% than with Restasis at weeks 4 and 8. Corneal surface scores, TBUT, SPEED, and OSDI scores improved in all groups at 4, 8, and 12 weeks without intergroup differences.
Conclusions
Low-concentration cyclosporine (SCAI-001 0.01% and SCAI-001 0.02%) demonstrated efficacy and safety comparable to that of Restasis in improving DED measures.
Trial registration
ClinicalTrials.gov Identifier: NCT05733624 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Pusan National University School of Medicine, Busan, South Korea.
- Department of Ophthalmology, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea.
- Department of Ophthalmology, Kangbuk Samsung Hospital, Seoul, South Korea.
- Department of Ophthalmology, Kyungpook National University Hospital, Daegu, South Korea.
- Department of Ophthalmology, The Catholic University of Korea, Bucheon ST. Mary's Hospital, Bucheon, South Korea.
- Department of Ophthalmology, Asan Medical Center, Seoul, South Korea.
ORCID-Profile: Hong Kyun Kim, Ji Eun Lee, Jong Soo Lee
Förderung
- SCAI Therapeutics
Zitieren
APA
Kim, J. H., Kim, H. K., Shin, Y. J., Choi, C. Y., Kim, H. K., Kim, E., Kim, J. Y., Lee, J. E., Kim, S., Hwang, M., Song, J. S., Kim, D. H., & Lee, J. S. (2026). Comparative study on the clinical effectiveness of low-concentration cyclosporine eye drops in patients with dry eye disease. PLOS One. https://doi.org/10.1371/journal.pone.0358007
Vancouver
Kim JH, Kim HK, Shin YJ, Choi CY, Kim HK, Kim E, et al. Comparative study on the clinical effectiveness of low-concentration cyclosporine eye drops in patients with dry eye disease. PLOS One. 2026. doi:10.1371/journal.pone.0358007
BibTeX
@article{Kim2026,
author = {Kim, Jae Hyun and Kim, Hui Kyung and Shin, Young-Joo and Choi, Chul Young and Kim, Hong Kyun and Kim, Eunchul and Kim, Jae Yong and Lee, Ji Eun and Kim, SunWoong and Hwang, Moonwon and Song, Jong-Seok and Kim, Dong Hyun and Lee, Jong Soo},
title = {Comparative study on the clinical effectiveness of low-concentration cyclosporine eye drops in patients with dry eye disease},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0358007}
}
EUVIMED